Project Details
Description
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator???s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
| Status | Active |
|---|---|
| Effective start/end date | 3/8/23 → 3/31/28 |
Funding
- IMMUNOCORE LTD.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.